<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CEFAZOLIN SODIUM <img border="0" src="../images/pr.gif"/></span><br/>(sef-a'zoe-lin)<br/><span class="topboxtradename">Ancef, </span><span class="topboxtradename">Kefzol, </span><span class="topboxtradename">Zolicef<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">first-generation cephalosporin</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg, 500 mg, 1 g, injection</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic, first-generation derivative of cephalosporin C; antibiotic activity similar to that of cefazolin. Activity
         against gram-negative organisms is limited. Bactericidal action: preferentially binds to one or more of the penicillin-binding
         proteins (PBP) located on cell walls of susceptible organisms. This inhibits third and final stage of bacterial cell wall
         synthesis, thus killing the bacterium.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective treatment for bone and joint infections, biliary tract infections, enocarditis prophylaxis and treatment, respiratory
         tract and genital tract infections, septicemia and skin infections, and surgical prophylaxis.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Severe infections of urinary and biliary tracts, skin, soft tissue, and bone, and for bacteremia and endocarditis caused by
         susceptible organisms; also perioperative prophylaxis in patients undergoing procedures associated with high risk of infection,
         e.g., open heart surgery.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to any cephalosporin and related antibiotics; pregnancy (category B), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of penicillin sensitivity, impaired renal function, patients on sodium restriction.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 250 mg2 g q8h, up to 2 g q4h (max: 12 g/d)<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> 25100 mg/kg/d in 34 divided doses, up to 100 mg/kg/d (not to exceed adult doses)<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 7 d: 4060 mg/kg/d divided q812h<br/><br/><span class="impairmenttitle">Adjustment for Renal Impairment</span><br/>Cl<sub>cr</sub> <br/><span class="indicationtitle">Surgical Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 12 g 3060 min before surgery, then q8h for 24 h<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> 2550 mg/kg 3060 min before surgery, then q8h for 24 h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Preparation of IM solution: Reconstitute with sterile water for injection, bacteriostatic water for injection, or 0.9%
            sodium chloride injection. Reconstituted solutions are stable for 24 hr at room temperature and for 96 hr refrigerated.
         </li>
<li>IM injections should be made deep into large muscle mass. Pain on injection is usually minimal. Rotate injection sites.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>IV administration to neonates, infants, and children: Verify correct IV concentration and rate of infusion with physician.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute each 1 g with 10 mL of sterile water for injection.   <span class="methodtype">Intermittent:</span> Further dilute with 50100 mL of NS or D5W.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct/</span><span class="methodtype">Intermittent:</span> Infuse 1 g over 5 min or longer as determined by the amount of solution. The risk of IV site reactions may be reduced by proper
                  dilution of IV solution, use of small bore IV needle in a large vein, and by rotating injection sites.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<span class="classification">aminoglycosides</span>, <b>ascorbic acid,</b>
<b>atracurium,</b>
<b>bleomycin,</b>
<b>cimetidine,</b>
<b>hydromorphone,</b>
<b>lidocaine,</b>
<b>ranididine,</b>
<b>vitamin B complex with C.</b>
<span class="incompattype">Y-site:</span>
<b>Amiodarone,</b>
<span class="classification">aminoglycosides</span>, <b>amphotericin B cholesteryl complex,</b>
<b>idarubicin,</b>
<b>pentamidine,</b>
<b>vinorelbine.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span>
<span class="speceff-life">Anaphylaxis</span>, fever, eosinophilia, superinfections, seizure (high doses in patients with renal insufficiency). <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea,</span> anorexia, abdominal cramps. <span class="typehead">Skin:</span> Maculopapular rash, urticaria. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Because of cefazolin effect on the <span class="alt">direct Coombs' test,</span> transfusion <span class="alt">cross-matching procedures</span> and <span class="alt">hematologic studies</span> may be complicated. False-positive <span class="alt">urine glucose</span> determinations are possible with use of <span class="alt">copper sulfate tests</span> (e.g., <span class="alt">Clinitest</span> or <span class="alt">Benedict's reagent</span>) but not with <span class="alt">glucose oxidase tests</span> such as <span class="alt">TesTape,</span>
<span class="alt">Diastix,</span> or <span class="alt">Clinistix.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Probenecid</b> decreases renal elimination of cefazolin. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 12 h after IM; 5 min after IV. <span class="typehead">Distribution:</span> Poor CNS penetration even with inflamed meninges; high concentrations in bile and in diseased bone; crosses placenta. <span class="typehead">Elimination:</span> 70% excreted unchanged in urine in 6 h; small amount excreted in breast milk. <span class="typehead">Half-Life:</span> 90130 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine history of hypersensitivity to cephalosporins, penicillins, and other drugs, before therapy is initiated.</li>
<li>Lab tests: Perform culture and sensitivity testing prior to and during therapy. Therapy may be initiated pending results.</li>
<li>Monitor I&amp;O rates and pattern: Be alert to changes in BUN, serum creatinine.</li>
<li>If patient has had a reaction to penicillin, be alert to signs of hypersensitivity with use of cefazolin. Cross-allergenicity
            between cephalosporins and penicillin has been reported. Prompt attention should be given to onset of signs of hypersensitivity
            (see Appendix F).
         </li>
<li>Promptly report the onset of diarrhea, which may or may not be dose related. It is seen especially in patients with history
            of drug-related GI disturbances. Pseudomembranous colitis, a potentially life-threatening condition, starts with diarrhea.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly any signs or symptoms of superinfection (see Appendix F).</li>
<li>Report signs of hemostatic defects: ecchymoses, petechiae, nosebleed.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>